Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Drug Dev Res ; 85(1): e22151, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38349254

ABSTRACT

Drug repurposing is used to propose new therapeutic perspectives. Here, we introduce "Drug Upgrade", that is, characterizing the mode of action of an old drug to generate new chemical entities and new therapeutics. We proposed a novel methodology covering target identification to pharmacology validation. As an old drug, we chose hydroxychloroquine (HCQ) for its well-documented clinical efficacy in lupus and its side effect, retinal toxicity. Using the Nematic Protein Organization Technique (NPOT®) followed by liquid chromatography-tandem mass spectrometry analyses, we identified myeloperoxidase (MPO) and alpha-crystallin ß chain (CRYAB) as primary and secondary targets to HCQ from lupus patients' peripheral blood mononuclear cells (PBMCs) and isolated human retinas. Surface plasmon resonance (SPR) and enzymatic assays confirmed the interaction of HCQ with MPO and CRYAB. We synthesized INS-072 a novel analog of HCQ that increased affinity for MPO and decreased binding to CRYAB compared to HCQ. INS-072 delayed cutaneous eruption significantly compared to HCQ in the murine MRL/lpr model of spontaneous lupus and prevents immune complex vasculitis in mice. In addition, long-term HCQ treatment caused retinal toxicity in mice, unlike INS-072. Our study illustrates a method of drug development, where new applications or improvements can be explored by fully characterizing the drug's mode of action.


Subject(s)
Drug Development , Leukocytes, Mononuclear , Humans , Animals , Mice , Mice, Inbred MRL lpr , Drug Repositioning , Hydroxychloroquine
2.
Sci Rep ; 8(1): 6577, 2018 04 26.
Article in English | MEDLINE | ID: mdl-29700325

ABSTRACT

A deficient activity of one or more of the mitochondrial oxidative phosphorylation (OXPHOS) enzyme complexes leads to devastating diseases, with high unmet medical needs. Mitochondria, and more specifically the OXPHOS system, are the main cellular production sites of Reactive Oxygen Species (ROS). Increased ROS production, ultimately leading to irreversible oxidative damage of macromolecules or to more selective and reversible redox modulation of cell signalling, is a causative hallmark of mitochondrial diseases. Here we report on the development of a new clinical-stage drug KH176 acting as a ROS-Redox modulator. Patient-derived primary skin fibroblasts were used to assess the potency of a new library of chromanyl-based compounds to reduce ROS levels and protect cells against redox-stress. The lead compound KH176 was studied in cell-based and enzymatic assays and in silico. Additionally, the metabolism, pharmacokinetics and toxicokinetics of KH176 were assessed in vivo in different animal species. We demonstrate that KH176 can effectively reduce increased cellular ROS levels and protect OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system. Due to its dual activity as antioxidant and redox modulator, KH176 offers a novel approach to the treatment of mitochondrial (-related) diseases. KH176 efficacy and safety are currently being evaluated in a Phase 2 clinical trial.


Subject(s)
Chromans/pharmacology , Mitochondria/metabolism , Mitochondrial Diseases/metabolism , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Peroxiredoxins/metabolism , Thioredoxins/metabolism , Apoptosis/drug effects , Cell Death/drug effects , Cell Line , Chromans/chemistry , Dose-Response Relationship, Drug , Electron Transport Complex I/deficiency , Glutathione/metabolism , Humans , Mitochondria/drug effects , Mitochondrial Diseases/etiology , Models, Molecular , Molecular Conformation , Molecular Structure , Oxidative Phosphorylation , Peroxiredoxins/chemistry , Reactive Oxygen Species/metabolism , Structure-Activity Relationship
3.
J Recept Signal Transduct Res ; 30(6): 444-53, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21091037

ABSTRACT

Melanocortin receptors (MCR) play an important role in the regulation of energy balance and autonomic function. In the present studies, we used active immunization against peptide sequences from the first and the third extracellular loop (EL1 and EL3) of the MC3R to generate selective antibodies (Abs) against this MCR subtype in rats. Immunization with the EL1 peptide resulted in Abs that enhanced the effects of the endogenous ligand α-melanocyte-stimulating hormone (α-MSH), whereas immunization with the EL3 peptide resulted in Abs acting as non-competitive antagonists. The phenotype of immunized rats chronically instrumented with telemetry transducers was studied under four different conditions: a high-fat diet was followed by standard lab chow, by fasting, and finally by an intraperitoneal injection of lipopolysaccharide (LPS). Under high-fat diet, food intake and body weight were higher in the EL3 than in the EL1 or the control group. Blood pressure was increased in EL3 rats and locomotor activity was reduced. Plasma concentrations of triglycerides, insulin, and leptin tended to rise in the EL3 group. After switching to standard lab chow, the EL1 group showed a small significant increase in blood pressure that was more pronounced and associated with an increase in heart rate during food restriction. No differences between the EL1 or the EL3 group were observed after LPS injection. These results show that immunization against the MC3R resulted in the production of Abs with positive or negative allosteric properties. The presence of such Abs induced small changes in metabolic and cardiovascular parameters.


Subject(s)
Antibodies/immunology , Autonomic Nervous System/physiology , Energy Metabolism/physiology , Receptor, Melanocortin, Type 3/chemistry , Receptor, Melanocortin, Type 3/immunology , Animals , Body Weight/immunology , Cyclic AMP/metabolism , Diet , HEK293 Cells , Humans , Male , Peptides/genetics , Peptides/immunology , Protein Conformation , Rats , Rats, Sprague-Dawley , Receptor, Melanocortin, Type 3/genetics , Telemetry
4.
J Clin Endocrinol Metab ; 94(3): 793-800, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19050052

ABSTRACT

BACKGROUND: The melanocortin-4 receptor (MC4R) is part of an important pathway regulating energy balance. Here we report the existence of autoantibodies (autoAbs) against the MC4R in sera of obese patients. METHODS: The autoAbs were detected after screening of 216 patients' sera by using direct and inhibition ELISA with an N-terminal sequence of the MC4R. Binding to the native MC4R was evaluated by flow cytometry, and pharmacological effects were evaluated by measuring adenylyl cyclase activity. RESULTS: Positive results in all tests were obtained in patients with overweight or obesity (prevalence, 3.6%) but not in normal weight patients. The selective binding properties of anti-MC4R autoAbs were confirmed by surface plasmon resonance and by immunoprecipitation with the native MC4R. Finally, it was demonstrated that these autoAbs increased food intake in rats after passive transfer via intracerebroventricular injection. CONCLUSION: These observations suggest that inhibitory anti-MC4R autoAbs might contribute to the development of obesity in a small subpopulation of patients.


Subject(s)
Autoantibodies/blood , Obesity/immunology , Receptor, Melanocortin, Type 4/immunology , Adult , Aged , Animals , Blood-Brain Barrier , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoprecipitation , Male , Middle Aged , Obesity/etiology , Rats , Rats, Sprague-Dawley , Surface Plasmon Resonance
SELECTION OF CITATIONS
SEARCH DETAIL